SUPPLEMENTARY TABLE S1: Sensitivity analysis, including ECOG performance status and Charlson comorbidity index.		
Variable	**Hazard ratio (95% CI)**	**p-value**
Age (per year increase)	1.06 (0.99-1.13)	0.086
Surgical procedure (biopsy vs. debulking)	1.36 (0.24-7.80)	0.728
Adjuvant therapy (RT alone vs. RT + TMZ)	1.52 (0.65-3.53)	0.337
Tumor grade (overall)	—	0.069
Grade 3 vs. grade 1	5.69 (0.76-42.69)	0.091
Grade 3 vs. grade 2	1.69 (0.62-4.63)	0.306
Tumor location (non-supratentorial vs. supratentorial)	8.70 (1.27-59.01)	0.028
Postoperative edema (present vs. absent)	3.34 (1.17-9.55)	0.024
ECOG (≥1 vs. 0)	1.65 (0.72-3.79)	0.234
Charlson comorbidity index (≥1 vs. 0)	2.93 (0.52-16.54)	0.223
Sensitivity analysis was performed using a multivariable Cox proportional hazards regression model including ECOG performance status and Charlson comorbidity index to assess the robustness of the primary findings. ECOG: Eastern Cooperative Oncology Group; RT: Radiotherapy; TMZ: Temozolomide; CI: Confidence interval.		